CN1074219A - New 10-hydroxyl pheophytin a - Google Patents
New 10-hydroxyl pheophytin a Download PDFInfo
- Publication number
- CN1074219A CN1074219A CN92115272A CN92115272A CN1074219A CN 1074219 A CN1074219 A CN 1074219A CN 92115272 A CN92115272 A CN 92115272A CN 92115272 A CN92115272 A CN 92115272A CN 1074219 A CN1074219 A CN 1074219A
- Authority
- CN
- China
- Prior art keywords
- cpd
- pheophytin
- acceptable salt
- pharmacy acceptable
- chlorophyll
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003839 salts Chemical class 0.000 claims abstract description 19
- 238000000034 method Methods 0.000 claims description 32
- 206010028980 Neoplasm Diseases 0.000 claims description 30
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 claims description 26
- 229930002868 chlorophyll a Natural products 0.000 claims description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 21
- 201000011510 cancer Diseases 0.000 claims description 16
- 239000000284 extract Substances 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 12
- 239000002904 solvent Substances 0.000 claims description 12
- CQIKWXUXPNUNDV-AXRVZGOCSA-N pheophytin a Chemical compound N1C(C=C2[C@H]([C@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)C(=N2)C2=C3NC(=C4)C(C)=C3C(=O)[C@@H]2C(=O)OC)C)=C(C)C(C=C)=C1C=C1C(C)=C(CC)C4=N1 CQIKWXUXPNUNDV-AXRVZGOCSA-N 0.000 claims description 11
- 241000255789 Bombyx mori Species 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- 238000002560 therapeutic procedure Methods 0.000 claims description 8
- 230000003287 optical effect Effects 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- 238000007796 conventional method Methods 0.000 claims description 4
- 238000000605 extraction Methods 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 229930002875 chlorophyll Natural products 0.000 claims description 3
- 235000019804 chlorophyll Nutrition 0.000 claims description 3
- 230000004060 metabolic process Effects 0.000 claims description 3
- 230000008961 swelling Effects 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 229910001425 magnesium ion Inorganic materials 0.000 claims description 2
- 238000013375 chromatographic separation Methods 0.000 claims 1
- 239000003504 photosensitizing agent Substances 0.000 abstract description 23
- 150000001875 compounds Chemical class 0.000 abstract description 16
- 238000011275 oncology therapy Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 33
- 241000699666 Mus <mouse, genus> Species 0.000 description 30
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 24
- 239000000243 solution Substances 0.000 description 23
- 238000002428 photodynamic therapy Methods 0.000 description 19
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 17
- 210000004881 tumor cell Anatomy 0.000 description 14
- 238000004809 thin layer chromatography Methods 0.000 description 13
- ZKSVYBRJSMBDMV-UHFFFAOYSA-N 1,3-diphenyl-2-benzofuran Chemical compound C1=CC=CC=C1C1=C2C=CC=CC2=C(C=2C=CC=CC=2)O1 ZKSVYBRJSMBDMV-UHFFFAOYSA-N 0.000 description 12
- 238000005286 illumination Methods 0.000 description 12
- 206010034972 Photosensitivity reaction Diseases 0.000 description 11
- 239000012071 phase Substances 0.000 description 11
- 230000004083 survival effect Effects 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 230000003647 oxidation Effects 0.000 description 10
- 238000007254 oxidation reaction Methods 0.000 description 10
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 239000000047 product Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 210000001015 abdomen Anatomy 0.000 description 6
- -1 as its metal-salt Chemical class 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 238000004811 liquid chromatography Methods 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- 229960001866 silicon dioxide Drugs 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 239000000287 crude extract Substances 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 150000004032 porphyrins Chemical class 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
- 231100000987 absorbed dose Toxicity 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000002329 infrared spectrum Methods 0.000 description 4
- 230000036211 photosensitivity Effects 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 4
- 238000006862 quantum yield reaction Methods 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 238000004007 reversed phase HPLC Methods 0.000 description 4
- 230000001235 sensitizing effect Effects 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 241000219315 Spinacia Species 0.000 description 3
- 235000009337 Spinacia oleracea Nutrition 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000003760 hair shine Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 2
- 235000016425 Arthrospira platensis Nutrition 0.000 description 2
- 240000002900 Arthrospira platensis Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000008033 biological extinction Effects 0.000 description 2
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 229910001873 dinitrogen Inorganic materials 0.000 description 2
- 229910001882 dioxygen Inorganic materials 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 238000002211 ultraviolet spectrum Methods 0.000 description 2
- OBSLWIKITOYASJ-YDEIVXIUSA-N (3r,4r,5s,6r)-6-(hydroxymethyl)-3-(methylamino)oxane-2,4,5-triol Chemical class CN[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OBSLWIKITOYASJ-YDEIVXIUSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- KIIGPNDJMVHUSL-UHFFFAOYSA-N 1-phenyl-2-benzofuran Chemical compound C=12C=CC=CC2=COC=1C1=CC=CC=C1 KIIGPNDJMVHUSL-UHFFFAOYSA-N 0.000 description 1
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- XJUCCCFALXAWMW-UHFFFAOYSA-N 2-benzofuran;1,1'-biphenyl Chemical compound C1=CC=CC2=COC=C21.C1=CC=CC=C1C1=CC=CC=C1 XJUCCCFALXAWMW-UHFFFAOYSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical class CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- KKAJSJJFBSOMGS-UHFFFAOYSA-N 3,6-diamino-10-methylacridinium chloride Chemical compound [Cl-].C1=C(N)C=C2[N+](C)=C(C=C(N)C=C3)C3=CC2=C1 KKAJSJJFBSOMGS-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- UJKPHYRXOLRVJJ-MLSVHJFASA-N CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C Chemical class CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C UJKPHYRXOLRVJJ-MLSVHJFASA-N 0.000 description 1
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 238000001157 Fourier transform infrared spectrum Methods 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical group CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 description 1
- 206010029098 Neoplasm skin Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical class C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000006268 Sarcoma 180 Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical class OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 239000006035 Tryptophane Substances 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 238000003811 acetone extraction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical class C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical class C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- XTEGARKTQYYJKE-UHFFFAOYSA-N chloric acid Chemical compound OCl(=O)=O XTEGARKTQYYJKE-UHFFFAOYSA-N 0.000 description 1
- 238000002983 circular dichroism Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical class OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000005558 fluorometry Methods 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 230000005283 ground state Effects 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229910052500 inorganic mineral Chemical class 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- QDLAGTHXVHQKRE-UHFFFAOYSA-N lichenxanthone Natural products COC1=CC(O)=C2C(=O)C3=C(C)C=C(OC)C=C3OC2=C1 QDLAGTHXVHQKRE-UHFFFAOYSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 230000005291 magnetic effect Effects 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical class C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 239000011707 mineral Chemical class 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 150000002926 oxygen Chemical class 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 230000000886 photobiology Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004237 preparative chromatography Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical class CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 231100000489 sensitizer Toxicity 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- QTENRWWVYAAPBI-YCRXJPFRSA-N streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O QTENRWWVYAAPBI-YCRXJPFRSA-N 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 239000006200 vaporizer Substances 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
The invention relates to new 10-hydroxyl pheophytin a (following be referred to as sometimes " CpD-I ") and its pharmacy acceptable salt, and the preparation method of this compound.The invention still further relates to the photosensitiser composition that contains as the above-claimed cpd of active ingredient, and utilize above-mentioned optical dynamic therapy method for cancer.
In recent years, " photodynamic therapy (PDT) " caused the interest and the concern of medical circle, and so-called " photodynamic therapy (PDT) " is meant the therapy of utilizing actinic rays kill tumor cell.T.J.Dougherty has reported representative this photodynamic therapy.This photodynamic therapy comprises the use photosensitizers, this photosensitizers by preferential absorption in solid tumor growth tissue part rapidly.In a single day photosensitizers is injected into, and just is enriched in around the tumor locus.Then to the light of the inherent maximum absorption wavelength of tumour photosensitizer administration own, so that kill tumor cell and do not damage healthy cell around the tumour cell optionally [referring to people such as T.J.Dougherty, Cancer Res.38, PP.2628-2635(1978)].
When utilizing photodynamic therapy treatment cancer, key is to select used photosensitizers.Photosensitizers should have the preferential also specificity of emitting fluorescence that combines with tumour cell.By utilizing these character can the localization of cancer cell.In photosensitizers injects checked health body, in health, behind the placement endoscope, be easy to observe the fluorescence position, i.e. the growth of tumour cell position then.
During irradiation, be in the sensitiser absorption light of ground state.The photoexcited state of photosensitizers shifts energy to intravital molecular oxygen, produces singlet oxygen.The various biological compounds of singlet oxygen oxidation comprise cellularstructure component such as steroide and the phosphatide with unsaturated acyl group chain, amino acid such as tryptophane, Histidine, light Gelucystine and methionine(Met); And nucleic acid component such as guanosine and cytidine or the like.Therefore, in case singlet oxygen and tumour cell effect, it will be by the cellular component kill tumor cell of oxidation tumor tissues.
As mentioned above, photodynamic therapy can be used for the diagnosis and the treatment field of cancer.Photodynamic therapy is better than the methods of treatment of other type.This methods of treatment has good therapeutic action and very wide range of application, even steal mirror in also can passing by light and treat with succeeding because be in the tumour (no matter be what tumour) at any remote position.This methods of treatment also has another advantage, and promptly it only produces less side effect for normal cell, but thereby repetitive administration.
Up to now, a large amount of photosensitizerss have been developed, the wherein existing natural synthetic that also has.These photosensitizerss comprise psoraline, flavine, porphyrin, acridine, thiodiphenylamine, xanthene, quinone, polyenoid, halogenated aromatic compound, and mineral ion is [referring to J.D.Spikes and R.Livingston, Advances in Radiation Biology, Vol, II, PP.29-121(1969)].Many this photosensitizerss now have been used as light power antineoplastic agent and have been used for clinical trial.A small amount of photosensitizers can have been bought from the market and be used for PDT.Its representative example comprises that hematoporphyrin derivative (HpD) is (by The Quadra Logic Technology Inc(Vancouver, Canada) sell, trade name is " a Photofrin-I ", the mixture of the ether of polyhematoporphyrin ether and ester in one, " Photofrin-II ", a kind of purer product.
Inventor of the present invention concentrates and has carried out a series of tests, so that seek a kind of effective photosensitizers with good result of treatment, found that isolated new phoeophytin derivative can greatly improve photosensitivity from the silkworm extract, thereby finished the present invention.
Therefore, the purpose of this invention is to provide new phoeophytin derivative, this derivative can be used as photosensitizers and is used for photodynamic therapy treatment cancer.
Another object of the present invention provides the method for the new phoeophytin derivative of preparation the present invention.
Another object of the present invention provides photosensitiser composition, and it comprises as the new phoeophytin derivative of the present invention of activeconstituents with it and mixing and the bonded usual component, as carrier, and vehicle, swelling agent or the like.
Still a further object of the present invention provides the new phoeophytin derivative optical dynamic therapy method for cancer with the present invention.
The rest part of other purpose of the present invention by reading specification sheets is with fully aware of.
Accompanying drawing 1A and 1B represent various silkworm extracts, the thin-layer chromatography of spinach and Sang Zi (TLC);
Accompanying drawing 2A, 2B and 2C represent to be described among accompanying drawing 1A and the 1B with 2 reversed phase high efficiency liquid chromatography (HPLC); Wherein accompanying drawing 2A be illustrated under the fluorescence compartment lamp exposure after several hours with 2 reversed phase high efficiency liquid chromatography, its expression is converted to CpD-2 by CpD-1 light; Accompanying drawing 2B be illustrated under the lamp exposure after 5 minutes with 2 reversed phase high efficiency liquid chromatography; Accompanying drawing 2C represent without exposure with 2 reversed phase high efficiency liquid chromatography;
Accompanying drawing 3A represents CpD-1 and chlorophyll a separately
1H-NMR spectrum, wherein arrow indication C
10-OH and C
10The position of-H;
Accompanying drawing 3C represents CpD-1's
13C-NMR spectrum;
Accompanying drawing 3D represents CpD-1's
1H two dimension COZY NMR spectrum;
The Fourier Tranform infrared spectra of accompanying drawing 4 expression CpD-1;
Accompanying drawing 5 is illustrated under 295 ° of K 1, the chart of the creating singlet oxygen by using quantity that produces during the maximum initial light rate of oxidation of 3-phenyl isobenzofuran (DPBF);
The absorbability of CpD-1 and HpD in accompanying drawing 6 expression tumours and the normal cell; And
Accompanying drawing 7A and 7B represent to use CpD-1 and HpD difference human body T-4 lymphoma cell line (MOLT-4) and human body end blood lymphocytes (PBL) slightly, are exposed to the percentage survival of the above-mentioned cell in ruddiness (accompanying drawing 7A) and gold-tinted (accompanying drawing 7B) back then.
The invention provides new 10-hydroxyl pheophytin or its pharmaceutically acceptable salt with following formula:
Pheophytin derivative of the present invention can high yield produce the light activation creating singlet oxygen by using, compares with other sensitising agent commonly used, demonstrates better selection and absorb in tumor tissues. In addition, aspect the selection destruction of cancer cells and treatment tumour efficient of experimental animal, sensitising agent of the present invention is more superior than other sensitising agent commonly used.
The The compounds of this invention structure is similar to chlorophyll a, but still has architectural feature, i.e. Mg in the chlorophyll a++And C10Hydrogen atom is replaced by two hydrogen atoms and hydroxyl respectively on the position.
Known to the inventor, 10-hydroxyl pheophytin of the present invention is the noval chemical compound that structure also was not determined, and also is not used as sensitising agent in vivo with in the in vitro test.
The formula I compound is convertible into its non-toxic salt, i.e. its pharmacy acceptable salt that obtains according to any ordinary method.Described non-toxic salt comprises the inorganic salt of formula I compound, as its metal-salt, and inorganic acid salt and organic salt.Metal-salt comprises an alkali metal salt such as sodium salt, sylvite etc., and alkaline earth salt, and as calcium salt, magnesium salts etc.Inorganic acid salt can comprise hydrogen chlorate, hydrobromate, vitriol, phosphoric acid salt or the like.Organic salt can comprise organic amine salt, as front three amine salt, triethylamine salt, pyridinium salt, procaine salt, picoline salt, dicyclohexyl amine salt, N, N-dibenzyl-1, the 2-ethylenediamine salt, N-methylglucosamine salt, diethanolamine salt, triethanolamine salt, three-(methylol amino) methane salt, phenylethyl benzylamine salt, dibenzyl ethylenediamine salt or the like.Non-toxic salt also comprises organic carboxyl acid or sulfonate, as formate, acetate, maleate, tartrate, mesylate, benzene sulfonate, tosylate etc., and with alkalescence or acidic amino acid such as arginine, aspartic acid, the salt that L-glutamic acid, Methionin etc. form.
The present invention also provides the method for preparing new phoeophytin derivative of the present invention, comprises step:
(a) from the silkworm extract, extract the chlorophyll metabolism thing with suitable solvent;
(b) substance dissolves that extraction is obtained is in suitable solution, to supersaturation;
(c), from gained solution, separate the photosensitizers component through chromatography; And
(d) collection shows the quick agency part of high light, uses the ordinary method purifying subsequently.
The extraction of silkworm extract (step (a)) can be carried out according to conventional solvent-extraction process, for solvent, can use known any solvent of this specialty such as ketone, alcohol, and composition thereof.The material that extracts is dissolved in the suitable solvent then, obtains a supersaturated solution (step (b)).Any solvent all can be used for the dissolved solids extract.Yet, be effective dissolving, preferred tertiary butanols, the mixture of acetone and pentane.Gained solution is then through chromatography, the solid ingredient (step (c)) of separate dissolved in extracting solution.The known any preparative chromatography of this specialty, as liquid chromatography (LC), thin-layer chromatography (TLC), and other class shape and color spectrum all can be used.After having separated, collect part, use conventional purification process purifying (step (d)) then with strong photosensitivity.The present invention preferably uses high pressure liquid chromatography (HPLC).
Analyze products therefrom, determine its chemical structure.Can use any analytical procedure known in the art, as infrared spectra (IR), Fu Liye changes infrared spectra (FT-IR), UV spectrum (UV), rotatory dispersion and circular dichroism, fluorometry, flash spectrum, mass spectrum, NMR (Nuclear Magnetic Resonance) spectrum etc.
In addition, the formula I compound also can be made raw material by utilizing chlorophyll a, and is synthetic with chemical process.The synthetic method of preparation formula I compound comprises the steps:
(a) with chlorophyll a under room temperature, in ethanol or chloroform,, slough Mg ion wherein with HCl reaction;
(b) under the safety lamp or dark situations of room temperature and dimness, in gained solution, slowly blasted air one day or the longer time, replace C with oh group
10Hydrogen atom on the position; With
(c) with products therefrom purifying according to a conventional method.
The raw material chlorophyll a can obtain from any suitable raw material with currently known methods, but preferred the use is rich in chlorophyllous marine alga, and Spirulina platensis is as the raw material of chlorophyll a.This synthetic method advantage is to be fit to produce by batch on a large scale CpD.
Although the above-mentioned part of the present invention has only been described single formula I compound, but should know, for similar compound, can carry out with the wherein substituent improvement foot of other substituting group replacement, referring to G.N.La Mar, " Model Compounds As Aids In Interpreting NMR Spectra of Hemoproteins " in Biological Applications of Magnetic Resonance, R.G.Shulman Ed., pp.305-343(1979), Academic Press, New York; And J.D.Satterlee, " NMR Spectroscopy of Paramagnetic Haem Proteins " in Annual Reports On NMR Spectroscopy, G.A.Webb Ed., pp.84-85(1986), Academic Press, New York.According to these prior arts, utilize ordinary method known in the art to be easy to design and have the substituent analogue different in a large number with the formula I compound with synthesizing, therefore, the present invention also comprises the 10-hydroxyl-pheophytin a analogue with following formula structure:
Wherein, R
1, R
3, R
4, R
5, R
6And R
8Represent C
1-C
3Alkyl aldehydes or C
3-C
5Cycloalkyl;
R
2Represent C
1-C
3Alkenyl, and
R
7Representative
Wherein 1, m and n represent 1 to 3 integer separately.
On the other hand, provide the photosensitiser composition that is used for the treatment of cancer cells, comprised active ingredient formula I compound or its pharmacy acceptable salt and mix or the bonded usual component with it, as carrier, vehicle, swelling agent, and other additive.
On the other hand, the invention provides the optical dynamic therapy method for cancer, comprise to health and use new formula I phoeophytin derivative or its pharmacy acceptable salt.
Formula I phoeophytin derivative can pass through various injecting methods such as intravenously, intramuscular, and subcutaneous and peritoneal injection feeds in the human body, and per daily dose is 5 milligrams to 10 milligrams of every kg body weight.
The present invention is described in more detail by following embodiment.Described embodiment only is used to illustrate the object of the invention, and should not be considered to be limited in strict the present invention who describes in claims.
Embodiment 1: prepared CpD-1 and determined its structure by the silkworm extract
According to conventional solvent-extraction process, from the silkworm extract, extract the chlorophyll metabolism thing with acetone.As a comparison, independently repeat identical extracting method with spinach with Sang Zi.
After the drying, the 0.1g crude extract is dissolved in the 1ml trimethyl carbinol, in the mixed solvent of the pentane of acetone (5: 60: 235V/V/V), obtain a supersaturated solution.Gained solution is put (20 * 20cm) (TLC plastic plate, Art, 5735, EM Science) on thin-layer chromatography (TLC) the plastics silica-gel plate according to a conventional method.After having put, the sample band is dry in nitrogen gas stream.Filter paper (25cm height) is placed in the TLC separation chamber (30 * 28 * 10cm), before launching, will pour in the separation chamber with the same solvent of above-mentioned dissolving usefulness in 20 minutes, be stamped the separation chamber of cover glass with the vacuum grease sealing.Developing time is about 40 minutes.All operations all carries out under dark or dim green glow.
The results are shown in shown in accompanying drawing 1A and the 1B.Referring to accompanying drawing 1A and 1B, for spinach and Sang Zi, in launching chromatogram second band (" being with 2 ") does not appear.In vivo test shows with 2 to have fabulous photosensitivity.
To be with 2 from the TLC plate, carefully to scrape, and acetone extraction.Elutriant evaporates in nitrogen gas stream then, preserves residue, so that be further purified.
Subsequently, according to the ordinary method reversed-phase HPLC, used instrument is ISCO type 2350 HPLC, 2360 type gradient sequencers, UV-5 extinction/fluorescence monitor (ISCO, Inc), and C-18 Dynamax-300
(1 * 25cm) post (Rainin Instrument Company, Inc.).The HPLC operational condition is as follows:
Flow velocity: 1.7ml/min,
Moving phase: 35% methyl alcohol and 65% acetonitrile,
Gradient: last 25 minutes to 100% moving phase from 80% moving phase and 20% water.
Use has absorbancy and is about 7.0(600nm) 200 μ l volume injected samples (about 25 μ g).Each operating time is set to about 80 minutes, and monitoring 660nm place's absorbancy also is stored in the microcomputer.Automatically collect each peak.Obtain P1, P2, P3 and four groups of peaks of R4 as describing among the accompanying drawing 2A-2C.
With reference to accompanying drawing 2A-2C, accompanying drawing 2A represents with 2 at the reversed-phase HPLC curve of fluorescence compartment lamp exposure after several hours; Accompanying drawing 2B represents with 2 at the reversed-phase HPLC curve of exposure after 5 minutes under the lamp; Accompanying drawing 2C represents unexposed with 2 reversed-phase HPLC curve, is CpD-1 corresponding to the main ingredient at the 3rd peak (P3), and after exposure under lamp, CpD-1 is oxidized to the isomer C pD-2 of CpD-1, corresponding to second peak (P2).
The high-purity C pD-1 that obtains thus is by utilizing FAB/MS,
1H-peacekeeping bidimensional COZY NMRS,
13C NMR and FT-IR determine its structure.
Accompanying drawing 3A represents CpD-1 and chlorophyll a
1H-NMR spectrum, wherein arrow is represented C in CpD-1 and the chlorophyll a respectively
10-OH and C
10The position of-H.The chemical shift of CpD-1 and chlorophyll a is listed in the following table 1.Accompanying drawing 3B represents CpD-1, with heavy water (D
2O) blended CpD-1 and chlorophyll a
1H-NMR spectrum.Accompanying drawing 3C and accompanying drawing 3D represent CpD-1's respectively
13C-NMR spectrum and CpD-1's
1H bidimensional COZY NMR spectrum.The FT-IR spectrum of accompanying drawing 4 expression CpD-1.
According to above-mentioned chart, can determine the structure of CpD-1, wherein the Mg in the chlorophyll a
++Replaced C by two hydrogen atoms
10Hydrogen atom is replaced by OH on the position.
Table 1
(δ,ppm)*
1H** chlorophyll a CpD-1
α 9.61 9.75
β 9.47 9.59
δ 8.63 8.75
2a 8.00 8.03
2b
t6.29 6.31
2b
*6.20 6.22
10-H/OH 6.27 5.57
P2 5.14 5.22
P1 4.49 4.56
8 4.44 4.53
7 4.24 4.20
4a 3.87 3.77
10b 3.87 3.76
3a 3.70 3.60
1a 3.41 3.44
5a 3.26 3.29
7a
12.64 2.95
7b
12.48 2.56
7a
22.34 2.26
7b
22.34 2.26
P4 1.88 1.91
4b 1.81 1.70
P3a 1.70 1.61
8a 1.57 1.10
P15 1.49 1.49
P(CH
2)
*→1.24 1.24
P15a?&?P16 0.84 0.84
P7?&?P11 0.78 0.79
Note: * solvent for use: CDCl
3
The * position is represented by the Fischer coding scheme.
Embodiment 2: synthetic CpD-1
The dry marine alga of about 40g (Spirulina platensis is available from Mexico City) is immersed in the 1L flask that contains 500ml methyl alcohol, to wherein adding 5ml0.01MKOH.Under dark situations, slowly blasted air 6 days to gained solution, refluxed 15 minutes at about 50 ℃ then.Gained solution is then poured 100ml methanol rinse residual substance into by filter paper filtering in the funnel.Filtrate was handled 3 minutes with the dense HCl of 1ml then.(Buchi, Switzerland) evaporation gained solution to volume is less than 30ml with the optically-active vaporizer.In the material that produces, add 200ml ddH then
2O and 200mlCCl
4After the separation, organic phase 200ml ddH
2The O washed twice is abandoned water.Organic solvent is further removed by evaporation, and the gained resistates is dissolved in about 20mlCCl
4In, obtain crude extract.
About 60g230 to 400 order silica gel (Sigma Chemical Co.) is immersed in CCl
4In, sonic treatment is 5 minutes then.Pillar is filled with 2.5 internal diameters (cm) Glass tubing, and uses CCl
4Pre-equilibration.Press similarity condition and fill second and the 3rd silicagel column.Be packed into after the crude extract, inject about 50ml CCl
4Pink and the yellow substance of drip washing.Inject the CCl that contains 20% acetone then
4Solution, wash-out 10-OH pheophytin a/the contain pheophytin a component of CpD.Abandon the residual substance in the post, evaporating solvent, residue are dissolved in 15ml CCl again
4In be used for silica gel chromatography for the second time.After in sample is filled into new silicagel column, with about 50ml CCl
4Wash-out is pink/yellow substance.Use the CCl of 10% acetone then
4Wash-out target CpD part.Equally can not be by the CCl of 10% acetone
4The surplus materials of wash-out abandons.Repeat solvent is steamed from the part of collecting, resistates is dissolved in 15ml CCl then
4After will being filled in the 3rd silicagel column from the sample that second silica gel obtains; Inject earlier about 150ml(enough till) contain the CCl of 2% acetone
4Solution, the non-target CpD(of wash-out utilize absorption spectrum to detect).Then will be up to the CCl that contains 5% acetone
4Drips of solution is added to moving phase, and wash-out contains 10-OH pheophytin a part.Dry collected part and dark preservation under nitrogen atmosphere are so that utilize reversed-phase column chromatography to be further purified.Aforesaid operations carries out in Fume Hoods.
Preparation type C-18 reversed-phase column (Chromosorb LC-1, Sigma Chemical Co.) is filled in long (cm) adjustable Glass tubings in 2.2 internal diameters * 12 (Amicon).Elution program is as follows:
Moving phase: 50% ethanol, 40% acetonitrile, and 10%CCl
4
Inject the about 250 μ g CpD of sample: 1ml
Flow velocity: 2ml/min
Detect: 660nm absorbs
Elution program: (1) from 99%M.P. and 1% water gradient elution 15 minutes to 100%M.P.
(2) the 100%M.P. wash-out is 13 minutes
(3) 20%CCl
4Aqueous isopropanol wash-out 7 minutes
(4) 99%M.P. and 1% water elution are 20 minutes.
Inject back 28 minutes wash-outs and go out 10-OH pheophytin a part.Through the TLC assay determination, products therefrom purity is greater than 95%.For TLC, this product unfolded Rf value is identical with crude extract second band of silkworm metabolite.The TLC analysis condition is described identical with embodiment 1.
The contriver has measured TLC stratographic band 1 by determining NMR proton/carbon spectrum, through comparing with 10-OH pheophytin a and chlorophyll a, is defined as pheophytin a.The retention time of pheophytin a is longer than 10-OH pheophytin a on the C-18 post, and they can not be separated under above-mentioned elution requirement.The 10-OH pheophytin a product of dry gained is also stored in the dark under nitrogen atmosphere.Productive rate: more than or equal to 0.4%, calculate, suppose that chlorophyll a 100% is extracted with the dry weight seaweed powder, (in fact the percentage extraction yield of every batch of chlorophyll a is all changing), this productivity ratio is high 10 times from the CpD productive rate (0.04) that the crude extract of silkworm extract obtains.
Embodiment 3: the singlet oxygen productive rate
One of most important index of measuring PDT photosensitizers maximum efficiency is exactly that it is by shifting the ability that produces singlet oxygen from the triplet state photosensitizers to the molecular oxygen energy.There are two kinds of independent solutions can measure the quantum yield of singlet oxygen, see described method I of present embodiment and method II.Photosensitized oxidation method (method I) uses 1, and 3-phenylbenzene isobenzofuran (DPBF) is as the singlet oxygen trapping agent.According to the minimizing of DPBF fluorescence or absorbancy, measure photosensitized oxidation speed, thus the initial photosensitized oxidation speed of estimation DPBF in the presence of various photosensitizerss.Initial photosensitized oxidation speed is inversely proportional to the initial rate that produces singlet oxygen.
Method I: the photosensitized oxidation of relative DPBF
Use 632.8nm he-Ne laser (maximum output 20mw, Metrologic Instruments, Inc.) as source of radiation, excited sample solution.Use freshly prepd DPBF(recrystallization under nitrogen atmosphere in the dark) ethanolic soln, concentration is utilized 420nm, ε=22,500cm
-1M
-1Detect.In containing the sealing cuvette that total amount is a 2ml solution, various photosensitizerss almost have identical absorbancy at 632nm.To slowly blast in the solution through the pre-saturated oxygen of solvent, and last 20 minutes, the DPBF with a small amount of five equilibrium different concns mixes with solution then.Measure DPBF at 455nm(ethanol) and 465nm(CCl
4) locate the relation with irradiation time of weakening of fluorescence intensity, determine the initial photosensitized oxidation speed of DPBF.
Method II: direct luminescent method
In order directly to detect singlet oxygen, measure near infrared phosphorescence.(Quantel YG-571-C), excites at the 355nm place to use Q-switch Nd:YAG laser apparatus.Silkworm CpD and chlorophyll a sample dissolution by being adjusted in 355nm place absorbancy to about 0.55, make sample concentration basic identical in the ethanol-OD of air saturation.
Intersect according to inverse, by 1/ speed to 1/[DPBF] coordinate diagram two reciprocal obtain maximum initial rate (accompanying drawing 5).The quantum yield of the singlet oxygen of chlorophyll a in ethanol (Φ △, X, ethanol) is by maximum initial rate, with respect to quantum yield (Φ △, ch1=0.57, the CCl of the singlet oxygen of known chlorophyll a in tetracol phenixin
4), calculate by following formula (I):
φΔ,x=φΔ,chl (Achl·[RATEmax]x)/(Ax·[RATEmax]chl) (1)
Formula (1) also can be used for calculating the quantum yield of various photosensitizerss in ethanol.The results are shown in following table 2 and the accompanying drawing 5.According to these results, can determine that the singlet productive rate of CpD-1 is higher than chlorophyll a.CpD-1 demonstrates high 20% productive rate than HpD.
Table 2
Singlet oxygen productive rate (Φ △) is measured by relative DPBF photosensitized oxidation (method I) and straight line luminescent method (method II)
Method parameter chlorophyll a CpD-1 CpD-2
I φΔof 0.44 0.50 0.52
(DPBF)
ox
The relative I Δ 1.00 1.01 ± 0.05 1.09 ± 0.04 of II
τΔ(μsec) 30.5±0.8 31.6±0.4 28.9±1.1
Relative φ Δ 1.00 1.05 ± 0.06 1.16 ± 0.05
φΔ 0.44 0.46±0.03 0.51±0.02
The extinction ability of embodiment 4:CpD-1 in tumour and normal cell
Utilize human body T-4 lymphocyte series (MOLT-4) standard tumour cell as a comparison, freshly prepd human body peripheral blood lymphocyte (PBL) is the standard healthy cell as a comparison, the cell sorption of assessment CpD-1 and HpD.
To 1 * 10
6Add the 1ml photosensitizers solution that contains 10 μ g/ml CpD-1 and HpD in the cell respectively, and in drum, cultivated 30 to 210 minutes.Culture is at 0 ℃, and 2, under the 000rpm centrifugal 5 minutes.The cell sheet that is settled out washs with cool physiological saline, and then centrifugal.In throw out, add 400 μ l DMF.Room temperature vibrate formed mixture and 4 ℃ centrifugal, get 300 μ l supernatant liquids and as cell extract.
In 300 μ l cell extracts, add 200 μ l distilled water and 500 μ l 1N hydrochloric acid, make it reach 1ml.Be determined at 660 and the CpD-1 at 550nm place and the absorbancy of HpD respectively.And the absorbancy comparison under presetted wavelength with measuring result and standardized solution, obtain the absorbed dose of test photosensitizers in cell.
The results are shown in shown in the accompanying drawing 6.From accompanying drawing 6, absorbed dose in cell increases with incubation time as can be seen, irrelevant with porphyrin and test cell category, absorbed dose is greater than the absorbed dose in the human body peripheral blood lymphocyte (PBL) of standard healthy cell as a comparison in MOLT-4.Using under the identical test cell, CpD shows bigger absorbancy than HpD.In sum, can determine preferentially to be absorbed at tumour cell position CpD-1, its locating effect is more than the high twice of HpD.
Embodiment 5: select to destroy tumour cell (in vitro tests)
Utilize with the foregoing description 2 in identical tumour and healthy cell, assess the selection destructiveness of CpD-1.
CpD-1 is injected into respectively contains 1 * 10
6In the tumour cell and healthy cell of cell.The cell that to handle thus shone 10 minutes under ruddiness then.Photosensitizers as a comparison injects the repetition same steps as with HpD replaced C pD-1.Calculate the cell survival percentage of every interval in the time of 1 hour in 8 hours after the illumination immediately.The results are shown in shown in the accompanying drawing 7A.
Found after illumination, can be killed fully in 2 hours through the MOLT-4 that CpD-1 handles and crossed by red light irradiation, and the survival rate time of the PBL that handles and handled by CpD-1 and shone through CpD-1 increases and reduces, and 8 hours survival rates reach 69.4% after the illumination.Handled by HpD and MOLT-4 that red light irradiation is crossed after illumination 8 hours the time survival rate be 83.4%, and the PBL that is crossed by HpD processing and red light irradiation after illumination 8 hours the time survival rate be 91.4%.
Repeat above-mentioned same steps as, but replace red light irradiation MOLT-4 and PBL with yellow.The results are shown in shown in the accompanying drawing 7B.
The survival rate of MOLT-4 after being handled by CpD-1 increases in time and reduces, and survival rate was 2.7% when gold-tinted shone back 8 hours, and the PBL survival rate when gold-tinted shines back 8 hours after being handled by CpD-1 is 81.5%.MOLT-4 survival rate when gold-tinted shines back 8 hours after being handled by HpD is 58.2%, and the survival rate of PBL when gold-tinted shines back 8 hours after being handled by HpD is 83.3%.
These presentation of results CpD-1 demonstrates higher cytotoxicity at long wave (ruddiness) than shortwave (gold-tinted).With skin-deep anti-, HpD shows than high cell toxicity under gold-tinted than under ruddiness.Nonetheless, the cytotoxicity of HpD is still much smaller than CpD-1.In a word, with respect to CpD-1, HpD is very ineffective.
In sum, can determine that CpD-1 is better than HpD with regard to the selectivity tumor destruction.
Embodiment 6: to the result of treatment (in vitro tests) of mouse skin tumour
Female C3H/HeJ mouse (the about 20g of body weight) and BA mastocarcinoma are used for this experiment.By injecting 1 μ l BA mastocarcinoma sheet in the back flank of acceptor mouse, import subcutaneous tumors.When tumor growth was transplanted the back about 10 days to diameter 6-7mm(), use PDT and treat.
In this PDT therapeutic process, the 1st group that includes 12 mouse is injected into two kinds of various dose CpD, injects back 24 hours, with the rayed of two kinds of different light dosages.
From 12 mouse of the 1st group, take out 6, handle (5mg/Kg), used the 670nm rayed then 24 hours with 0.2ml liquid storage 2.In 6 mouse, wherein 3 total light dosages of acceptance are 100J/cm
2, accept 300J/cm for other 3
2Other 6 mouse are injected into more heavy dose of liquid storage 2(0.4ml) (10mg/Kg), and inject back 24 hours rayed at CpD.Equally, wherein 3 mouse are accepted 100J/cm
2Light dosage, other 3 mouse are accepted 300J/cm
2Like this, under the same conditions, per 3 mouse have constituted the PDT treatment time group that accepts.
In the tripping device of the 2nd group that forms by 12 mouse PDT treatment, use same PDT condition, but just inject beginning optical processing in 4 hours at CpD.The above results is listed in table 3 and the table 4 respectively.
Table 3
PDT treatment result when injecting behind the CpD-1 24 hours
The regrowth of CpD dosage light dosage mouse quantity toxicity is cured
(mg/Kg) (J/cm
2)
5 100 3 - 3 -
5 300 31 dead-2
10 100 3 - - 3
10 300 32 dead-1
Table 4
PDT treatment result when injecting behind the CpD-1 4 hours
The regrowth of CpD dosage light dosage mouse quantity toxicity is cured
(mg/Kg) (J/cm
2)
5 100 3 - 3 3
5 300 31 is dead, and 2-2
1 loses pin
10 100 33 dead--
10 300 33 dead--
Embodiment 7: to the result of treatment (in vitro tests) of malignant tumour
Inject by subcutaneous abdomen, the ICR mouse is used the S-180 cell, thereby induce the malignant tumour that produces the 5-10mm size.The S-180 cell obtains by the long-time sarcoma inducing cell system-Sarcoma 180 that cultivates in ICR mouse body.
To test mouse and be divided into two groups, each group is handled with CpD-1 and HpD respectively.Two groups after handling like this are divided into two, obtain total 4 groups.Two groups of rayed twice that have the wavelength of maximum absorbance with porphyrin in four groups wherein, each 10 minutes.Illumination is to carry out in the time of 24 hours then when treating back 1 hour with photosensitizers earlier.Two groups of rayed twice with identical wavelength of in four groups another, each 10 minutes, illumination was to carry out after 48 hours then when treating back 24 hours with photosensitizers earlier.
Earlier after injecting CpD-1 1 hour the time, the group of twice of illumination shows 100% curative ratio (cure quantity/always treat quantity=20/20) in the time of 24 hours then, and the group of handling with HpD shows 80% curative ratio (16/20).These presentation of results: compare with HpD, CpD-1 has high light sensitization ability (P<0.025).
Equally, earlier after injecting CpD-1 24 hours the time, the group of twice of illumination shows 60% curative ratio (12/20) in the time of 48 hours then.And the group of handling with HpD shows 80% curative ratio (16/20).According to these results (P>0.1), can infer that CpD-1 retention time in tumour cell is very short, therefore, patient's rayed once more arranged to what handle through CpD-1 even in the relatively short time, the effect of illumination for the second time is also very little.As for HpD, because HpD for the second time cytotoxic effect such as flush, edema and skin pain, the patient who stands optical dynamic therapy has to and light was isolated 24 hours at least.[referring to Photobiology of Porphyrins, In Doiron DR, Gomer CJ eds., Porphyrin Localization and treatment of tumors, New York, Alan R Liss Inc., 1984, pp.19-39].
Above-mentioned experimental result discloses CpD-1 and all is better than HpD in every respect, can be effective as the photosensitizers of treatment tumour cell.
Embodiment 8: to the swollen result of treatment (in vitro tests) of abdomen
Inject by subcutaneous abdomen, the ICR mouse is used the S-180 cell, induce abdomen swollen, and mouse is divided into five groups.Every group comprises 10 mouse.According to the mouse body weight with the growth of handling the time increase situation, assessment CpD-1 is to the swollen result of treatment of abdomen.
Inject S-180 after 6th day (first group), with CpD-1 handle respectively by the 13rd day (second group) and the 20th day (the 3rd group) for each group, and respectively after injecting CpD-1 24 hours then, rayed was three times when 48 hours and 72 hours, each 10 minutes.Handle but not illumination with CpD-1 for the 4th group.Handle without CpD-1 for the 5th group.
More than in 50 days time limit, if the weight increase of processed mouse and the 5th group is basic identical and still live, then mouse is considered to cure fully after above-mentioned processing.For first group, 8 mouse are cured fully.For second group, only there are 3 mouse to be cured fully, and remain 7 continuation growth death in 35 days owing to body weight.For the 3rd group, all mouse are dead because the continuation of body weight increases in 35 days.Equally, for the 4th group, all mouse are the death owing to increasing rapidly of body weight in 35 days, and its initial weight of weight ratio when mouse is dead nearly weighs twice.
Above-mentionedly work out explanation for less tumor locus, the clearance rate of tumour is higher.Can conclude that utilizing PDT method, CpD-1 to can be used for treating abdomen swells.
Embodiment 9: to the inhibition effect of the reversed transcriptive enzyme of retroviral
Five times of diluting solns that at first prepare infectivity Gross leukosis virus (GLV).Wherein GLV has leukemic C by cultivating from the patient in substratum
3The TGV clone that obtains in the HeB/Fe mouse and obtaining (referring to Machala O, Bodyd R, Youn JK, and Barski G:Long-term in Vitro culture of pathogenic Gross Leukemia Virus in mouse thymusCells, Eur.J.Cancer 10,467-472,1974).Gained solution is handled with CpD-1, then rayed.Reverse transcriptase products is examined and determine by the toxicity of assessing virus.
GLV is inoculated into 1 * 10
5On the normal mice fetus cells, and containing 10% penicillin (100 units per ml), cultivating 24 hours in the essential substratum of the Eagle bottom line of Streptomycin sulphate (100 μ g/ml) and foetal calf serum.Follow rayed after adding CpD-1, culture is with trypsin treatment and use trypan blue staining so that calculating survivaling cell.To grind with stain remover by the centrifugal resulting virion of ultra-high speed, and react with active mixing solutions, this solution has measurement
3H dTTP combines the ability of level with reversed transcriptive enzyme.The mixture that is produced, is washed to glass filter paper by point sample, and drying utilizes scintillometer to measure intrinsic specific activity.
Virus after CpD-1 processing and rayed is showed 5000cpm or littler radioactivity, the enzyme product is had remarkable effect (promptly reducing) or enzyme (reversed transcriptive enzyme) is had significant photodynamic action, and do not have CpD-1 to handle but demonstrate greater than 40 through the comparative group that rayed is crossed, the 000cpm radioactivity, equally, through CpD-1 handle and the identical virus of illumination to the infectivity attenuating of mouse fetus cells.
According to these results, can infer that CpD-1 has antiviral activity.
As mentioned above, 10-hydroxyl pheophytin a of the present invention and pharmacy acceptable salt demonstrate the photosensitivity of improvement and good tumour cell absorbability.In addition, The compounds of this invention is being better than other conventional photosensitizers, especially HpD aspect the throughput of selecting destruction of cancer cells and singlet oxygen.Therefore The compounds of this invention is adapted in the photodynamic therapy application as photosensitizers.
Claims (5)
2, the pheophytin a described in the preparation claim 1 or the method for its pharmacy acceptable salt comprise the steps:
(a) from the silkworm extract, extract the chlorophyll metabolism thing with appropriate solvent;
(b) substance dissolves that extraction is obtained is in appropriate solvent, to supersaturation;
(c) gained solution is gone out photosensitive component through chromatographic separation; And
(d) collect to show the quick agency part of high light, subsequently purifying according to a conventional method.
3, the pheophytin a described in the preparation claim 1 or the method for its pharmacy acceptable salt comprise the steps:
(a) under the room temperature, chlorophyll a and HCl are reacted in ethanol or chloroform, slough Mg ion wherein;
(b) under the room temperature, under the safety lamp of dimness or in the dark, in the solution of gained, slowly blasted air one day or the longer time, replace C with hydroxyl
10Hydrogen atom on the position; And
(c) will generate product purifying according to a conventional method.
4, a kind of photosensitiser composition that is used for the optical dynamic therapy cancer, comprise as activeconstituents at the 10-hydroxyl pheophytin a described in the claim 1 or its pharmacy acceptable salt, with mix with it or the conventional component of bonded such as carrier, vehicle, swelling agent and other additive.
5, a kind of by giving in the body with the 10-carbonyl pheophytin a in the claim 1 or the optical dynamic therapy method for cancer of pharmacy acceptable salt.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR23164/91 | 1991-12-17 | ||
KR910023164 | 1991-12-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1074219A true CN1074219A (en) | 1993-07-14 |
Family
ID=19324965
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN92115272A Pending CN1074219A (en) | 1991-12-17 | 1992-12-17 | New 10-hydroxyl pheophytin a |
Country Status (5)
Country | Link |
---|---|
KR (1) | KR950013563B1 (en) |
CN (1) | CN1074219A (en) |
AU (1) | AU2956992A (en) |
MX (1) | MX9207313A (en) |
WO (1) | WO1993012114A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109568578A (en) * | 2018-11-22 | 2019-04-05 | 广西师范大学 | Natural biomass quantum dot and biomass quantum dot-copper nano-complex preparation method and applications |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5179120A (en) * | 1991-06-28 | 1993-01-12 | Cytopharm, Inc. | Porphycene compounds for photodynamic therapy |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SU1028671A1 (en) * | 1981-07-15 | 1983-07-15 | Ивановский Ордена Трудового Красного Знамени Химико-Технологический Институт | Process for preparing metal complexes of pheophytin |
-
1992
- 1992-11-27 WO PCT/KR1992/000067 patent/WO1993012114A1/en active Application Filing
- 1992-11-27 AU AU29569/92A patent/AU2956992A/en not_active Abandoned
- 1992-12-14 KR KR1019920024123A patent/KR950013563B1/en not_active IP Right Cessation
- 1992-12-16 MX MX9207313A patent/MX9207313A/en unknown
- 1992-12-17 CN CN92115272A patent/CN1074219A/en active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109568578A (en) * | 2018-11-22 | 2019-04-05 | 广西师范大学 | Natural biomass quantum dot and biomass quantum dot-copper nano-complex preparation method and applications |
Also Published As
Publication number | Publication date |
---|---|
WO1993012114A1 (en) | 1993-06-24 |
MX9207313A (en) | 1993-07-30 |
AU2956992A (en) | 1993-07-19 |
KR950013563B1 (en) | 1995-11-09 |
KR930012781A (en) | 1993-07-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1271746A (en) | Purified hematoporphyrin derivative for diagnosis and treatment of tumors, and method | |
CN1222526C (en) | Chlorophyll and bacteriochlorophyll esters, and their preparation | |
CN1250294C (en) | Photosensitive and method for production thereof | |
JPS625985A (en) | Novel tetrapyrrole compound | |
JPS61129163A (en) | Novel tetrapyrrole compound | |
JP5340953B2 (en) | Carboranyl porphyrins and their use | |
CN1161697A (en) | Beta, beta'-dihydroxy meso-substituted chlorin, bacteriochlorin, isobacteriochlorin and method for making same | |
US20130150314A1 (en) | Trioxacarcins and uses thereof | |
JP7043260B2 (en) | A novel dihydroporphyrin e6 derivative and a pharmaceutically acceptable salt thereof, a method for preparing the same and a use thereof. | |
CN1840531A (en) | Porphyrin-based compounds for tumor imaging and photodynamic therapy | |
CN106866721A (en) | A kind of silicon phthalocyanine derivative and its prepare biotin acceptor target silicon phthalocyanine sensitising agent application | |
Scourides et al. | Nature of the tumor-localizing components of hematoporphyrin derivative | |
CN1334728A (en) | Palladium-substd. bacteriochlorophll derivatives and use thereof | |
CN107417706A (en) | With light, the quick active chlorin Artesunate conjugate of sound and preparation method and application | |
KR20220098732A (en) | Pyrazolopyrimidine derivatives as HCK inhibitors for use in therapy, particularly in MYD88 mutated diseases | |
CN113956242A (en) | Photosensitizer for inducing immunogenic cell death and preparation method and application thereof | |
CN1074219A (en) | New 10-hydroxyl pheophytin a | |
KR101493889B1 (en) | Photosensitizer for photodynamic diagnosis or therapy and the manufacturing method | |
JPH01250381A (en) | Pheophorbide derivative | |
CN1211919A (en) | Radiosensitizing taxanes and their pharmaceutical preparations | |
JP4866854B2 (en) | Boronated metal phthalocyanine, process for its preparation, pharmaceutical composition having the same and use thereof | |
CN109651383B (en) | Compounds for photosensitizers and uses thereof | |
Morgan et al. | Synthesis of benzopurpurins isobacteriobenzopurpurins and bacteriobenzopurpurins | |
CN102827227A (en) | Silicon phthalocyanine modified by adenosine derivative and preparation method and application thereof | |
Minaeva et al. | Synthesis of novel chlorin e6 derivatives containing organophosphorus groups |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C01 | Deemed withdrawal of patent application (patent law 1993) | ||
WD01 | Invention patent application deemed withdrawn after publication |